Hospital stocks extended losses amid regulatory scrutiny over cancer-drug markups and pharmacy practices. Despite the selloff, Jefferies maintained Buy ratings on six healthcare companies, citing target-price upside ranging from 22% to 46% and strong projected EBITDA growth through FY29.